NACDS: Initial Findings of FTC’s PBM Study Demand Action
NACDS: “The Congress and states need no further validation for their bipartisan work to immediately confront pharmaceutical benefit manipulation that is devastating Americans, communities, and pharmacies of all sizes”
NACDS: “These harms are experienced brutally by pharmacies of diverse sizes and formats, including independents and chains, that do not receive preferential treatment from their vertically integrated plans and PBMs”